CMS's Medicare Price Negotiations Start Round Three

Why It Matters

The negotiations aim to curb rising prescription costs, delivering immediate savings for Medicare and setting pricing precedents for high‑cost specialty drugs. They also signal broader federal efforts to control drug prices across both Part D and Part B markets.

Key Takeaways

• CMS announces 15 new drugs for Medicare price cuts 2028.
• Cuts affect $27 billion spending, 6% of Medicare drug budget.
• Includes both Part D and Part B administered medicines.
• First renegotiation: Boehringer’s Tradjenta seeks additional discount.
• GLP‑1 agonist Trulicity joins list, targeting diabetes market.

Pulse Analysis

The Inflation Reduction Act gave the federal government a powerful lever to tame prescription‑drug inflation, and Medicare’s price‑negotiation program has become its flagship tool. After two pilot rounds that focused exclusively on Part D, the Centers for Medicare & Medicaid Services (CMS) unveiled the third tranche, expanding the scope to include physician‑administered biologics covered under Part B. By targeting high‑spending specialty therapies—ranging from diabetes GLP‑1 agonists to autoimmune biologics—the administration hopes to capture savings that flow directly to the Medicare trust fund while preserving patient access.

Round three’s roster features a mix of blockbuster brands: Eli Lilly’s Trulicity, Gilead’s Biktarvy, and Pfizer’s Xeljanz, alongside products traditionally billed under Part B such as Botox, Entyvio, and Xolair. The inclusion of Part B drugs marks a strategic shift, acknowledging that a sizable share of specialty‑drug expenditures occurs in clinical settings. For manufacturers, the mandatory discounts—averaging around 10‑15 %—compress profit margins and may spur pricing reforms or accelerated launch of next‑generation therapies. Insurers and pharmacy benefit managers will need to adjust rebate structures and formulary placements to accommodate the new pricing baseline.

Looking ahead, the first renegotiation of Boehringer Ingelheim’s Tradjenta signals that CMS is prepared to revisit earlier agreements, tightening the net around drugs that retain high price growth. Industry observers expect further rounds to incorporate more Part B agents and potentially extend negotiations to biologics used in oncology. The evolving landscape underscores a broader policy trend: federal authorities are increasingly willing to intervene in drug pricing, compelling stakeholders to balance innovation incentives with affordability imperatives.